An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Tasurgratinib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 19 Nov 2024 Planned End Date changed from 30 Nov 2024 to 30 Nov 2026.
- 19 Nov 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Nov 2026.
- 18 Mar 2024 Planned End Date changed from 1 Aug 2024 to 30 Nov 2024.